Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 19.9% | Goldman Sachs | → $5 | Initiates Coverage On | → Neutral |
| 08/23/2023 | 235.73% | HC Wainwright & Co. | $5 → $14 | Upgrades | Neutral → Buy |
| 08/22/2023 | 283.69% | Oppenheimer | → $16 | Reiterates | Outperform → Outperform |
| 08/22/2023 | 163.79% | Stifel | → $11 | Upgrades | Hold → Buy |
| 08/04/2023 | 19.9% | HC Wainwright & Co. | → $5 | Reiterates | Neutral → Neutral |
| 05/16/2023 | 283.69% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 05/16/2023 | 19.9% | HC Wainwright & Co. | $6 → $5 | Maintains | Neutral |
| 05/05/2023 | -28.06% | Goldman Sachs | $9 → $3 | Maintains | Neutral |
| 05/04/2023 | -28.06% | Goldman Sachs | $9 → $3 | Downgrades | Buy → Neutral |
| 03/13/2023 | 115.83% | Goldman Sachs | $17 → $9 | Maintains | Buy |
| 03/10/2023 | 67.87% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
| 03/10/2023 | 43.88% | HC Wainwright & Co. | $20 → $6 | Downgrades | Buy → Neutral |
| 03/10/2023 | 91.85% | Credit Suisse | $11 → $8 | Downgrades | Outperform → Neutral |
| 02/28/2023 | 379.62% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/28/2023 | 91.85% | Morgan Stanley | $27 → $8 | Downgrades | Overweight → Equal-Weight |
| 02/27/2023 | 379.62% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/27/2023 | 379.62% | Oppenheimer | $26 → $20 | Maintains | Outperform |
| 02/27/2023 | 163.79% | Credit Suisse | $19 → $11 | Maintains | Outperform |
| 01/24/2023 | 547.48% | Morgan Stanley | $26 → $27 | Maintains | Overweight |
| 01/23/2023 | 403.6% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 01/19/2023 | 307.67% | Goldman Sachs | $11 → $17 | Maintains | Buy |
| 11/15/2022 | 163.79% | Goldman Sachs | → $11 | Initiates Coverage On | → Buy |
| 11/14/2022 | 523.5% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 11/09/2022 | 355.64% | Credit Suisse | $22 → $19 | Maintains | Outperform |
| 06/13/2022 | 379.62% | HC Wainwright & Co. | $40 → $20 | Maintains | Buy |
| 05/17/2022 | 499.52% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 04/12/2022 | 523.5% | Morgan Stanley | $25 → $26 | Maintains | Overweight |
| 03/25/2022 | 739.33% | Credit Suisse | $30 → $35 | Maintains | Outperform |
| 03/08/2022 | 691.37% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 08/17/2021 | 859.23% | HC Wainwright & Co. | $20 → $40 | Maintains | Buy |
| 08/13/2021 | 787.29% | SVB Leerink | $23 → $37 | Maintains | Outperform |
| 08/11/2021 | 619.42% | Credit Suisse | $20 → $30 | Maintains | Outperform |
| 08/11/2021 | 715.35% | Morgan Stanley | → $34 | Upgrades | Equal-Weight → Overweight |
| 03/22/2021 | 523.5% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 03/08/2021 | 187.77% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 03/02/2021 | 331.65% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 11/10/2020 | 451.56% | SVB Leerink | $25 → $23 | Maintains | Outperform |
| 10/16/2020 | 427.58% | Piper Sandler | → $22 | Initiates Coverage On | → Overweight |
| 08/12/2020 | 163.79% | B of A Securities | → $11 | Downgrades | Neutral → Underperform |
| 08/12/2020 | 379.62% | HC Wainwright & Co. | $28 → $20 | Maintains | Buy |
| 08/12/2020 | 163.79% | Morgan Stanley | $29 → $11 | Downgrades | Overweight → Equal-Weight |
| 06/19/2020 | 451.56% | B of A Securities | $19 → $23 | Downgrades | Buy → Neutral |
| 06/17/2020 | 547.48% | BTIG | → $27 | Initiates Coverage On | → Buy |
| 03/06/2020 | 571.46% | HC Wainwright & Co. | $21 → $28 | Reiterates | → Buy |
| 01/23/2020 | 427.58% | B of A Securities | $19 → $22 | Maintains | Buy |
| 10/03/2019 | 403.6% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
| 08/12/2019 | 595.44% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 08/12/2019 | 355.64% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/25/2023 | 19.9% | 高盛 | →$5 | 開始承保 | →中性 |
| 2023/08/23 | 235.73% | HC Wainwright公司 | $5→$14 | 升級 | 中性→購買 |
| 2023年08月22日 | 283.69% | 奧本海默 | →$16 | 重申 | 跑贏→跑贏大盤 |
| 2023年08月22日 | 163.79% | Stifel | →$11 | 升級 | 持有→購買 |
| 08/04/2023 | 19.9% | HC Wainwright公司 | →$5 | 重申 | 中性→中性 |
| 2023年05月16日 | 283.69% | 奧本海默 | $20→$16 | 維護 | 跑贏大盤 |
| 2023年05月16日 | 19.9% | HC Wainwright公司 | $6→$5 | 維護 | 中性 |
| 05/05/2023 | -28.06% | 高盛 | $9→$3 | 維護 | 中性 |
| 05/04/2023 | -28.06% | 高盛 | $9→$3 | 評級下調 | 購買→中性 |
| 03/13/2023 | 115.83% | 高盛 | $17→$9 | 維護 | 買 |
| 03/10/2023 | 67.87% | 摩根士丹利 | $8→$7 | 維護 | 等重 |
| 03/10/2023 | 43.88% | HC Wainwright公司 | $20→$6 | 評級下調 | 購買→中性 |
| 03/10/2023 | 91.85% | 瑞士信貸 | $11→$8 | 評級下調 | 跑贏→中性 |
| 02/28/2023 | 379.62% | HC Wainwright公司 | →$20 | 重申 | →購買 |
| 02/28/2023 | 91.85% | 摩根士丹利 | $27→$8 | 評級下調 | 超重→等重 |
| 02/27/2023 | 379.62% | HC Wainwright公司 | →$20 | 重申 | →購買 |
| 02/27/2023 | 379.62% | 奧本海默 | $26→$20 | 維護 | 跑贏大盤 |
| 02/27/2023 | 163.79% | 瑞士信貸 | $19→$11 | 維護 | 跑贏大盤 |
| 01/24/2023 | 547.48% | 摩根士丹利 | $26→$27 | 維護 | 超重 |
| 2023年1月23日 | 403.6% | 派珀·桑德勒 | $18→$21 | 維護 | 超重 |
| 2023年1月19日 | 307.67% | 高盛 | $11→$17 | 維護 | 買 |
| 2022年11月15日 | 163.79% | 高盛 | →$11 | 開始承保 | →購買 |
| 2022年11月14日 | 523.5% | 摩根士丹利 | $25→$26 | 維護 | 超重 |
| 11/09/2022 | 355.64% | 瑞士信貸 | $22→$19 | 維護 | 跑贏大盤 |
| 2022/06/13 | 379.62% | HC Wainwright公司 | $40→$20 | 維護 | 買 |
| 2022/05/17 | 499.52% | 摩根士丹利 | $26→$25 | 維護 | 超重 |
| 04/12/2022 | 523.5% | 摩根士丹利 | $25→$26 | 維護 | 超重 |
| 03/25/2022 | 739.33% | 瑞士信貸 | $30→$35 | 維護 | 跑贏大盤 |
| 03/08/2022 | 691.37% | 奧本海默 | →$33 | 開始承保 | →跑贏大盤 |
| 2021/08/17 | 859.23% | HC Wainwright公司 | $20→$40 | 維護 | 買 |
| 2021/08/13 | 787.29% | SVB Leerink | $23→$37 | 維護 | 跑贏大盤 |
| 2021/08/11 | 619.42% | 瑞士信貸 | $20→$30 | 維護 | 跑贏大盤 |
| 2021/08/11 | 715.35% | 摩根士丹利 | →$34 | 升級 | 等重→超重 |
| 03/22/2021 | 523.5% | 瑞士信貸 | →$26 | 開始承保 | →跑贏大盤 |
| 03/08/2021 | 187.77% | 摩根士丹利 | $11→$12 | 維護 | 等重 |
| 03/02/2021 | 331.65% | Stifel | →$18 | 開始承保 | →購買 |
| 11/10/2020 | 451.56% | SVB Leerink | $25→$23 | 維護 | 跑贏大盤 |
| 10/16/2020 | 427.58% | 派珀·桑德勒 | →$22 | 開始承保 | →超重 |
| 2020年08月12日 | 163.79% | B of A證券 | →$11 | 評級下調 | 中性→表現不佳 |
| 2020年08月12日 | 379.62% | HC Wainwright公司 | $28→$20 | 維護 | 買 |
| 2020年08月12日 | 163.79% | 摩根士丹利 | $29→$11 | 評級下調 | 超重→等重 |
| 2020/06/19 | 451.56% | B of A證券 | $19→$23 | 評級下調 | 購買→中性 |
| 06/17/2020 | 547.48% | BTIG | →$27 | 開始承保 | →購買 |
| 03/06/2020 | 571.46% | HC Wainwright公司 | $21→$28 | 重申 | →購買 |
| 1/23/2020 | 427.58% | B of A證券 | $19→$22 | 維護 | 買 |
| 2019年10月03日 | 403.6% | HC Wainwright公司 | →$21 | 開始承保 | →購買 |
| 2019年08月12日 | 595.44% | 摩根士丹利 | →$29 | 開始承保 | →超重 |
| 2019年08月12日 | 355.64% | B of A證券 | →$19 | 開始承保 | →購買 |
What is the target price for Fulcrum Therapeutics (FULC)?
支點治療公司(FULC)的目標價格是多少？
The latest price target for Fulcrum Therapeutics (NASDAQ: FULC) was reported by Goldman Sachs on September 25, 2023. The analyst firm set a price target for $5.00 expecting FULC to rise to within 12 months (a possible 19.90% upside). 24 analyst firms have reported ratings in the last year.
高盛於2023年9月25日報道了支點治療公司(納斯達克：FULC)的最新目標價。這家分析公司將目標價定為5美元，預計FULC將在12個月內上漲至19.90%。去年有24家分析公司公佈了評級。
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
支點治療公司(FULC)的最新分析師評級是多少？
The latest analyst rating for Fulcrum Therapeutics (NASDAQ: FULC) was provided by Goldman Sachs, and Fulcrum Therapeutics initiated their neutral rating.
對支點治療公司(納斯達克代碼：FULC)的最新分析師評級是由高盛提供的，支點治療公司啟動了他們的中性評級。
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
支點治療公司(FULC)的下一次分析師評級將於何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與支點治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Fulcrum治療公司的上一次評級是在2023年9月25日提交的，所以你應該預計下一次評級將在2024年9月25日左右的某個時候提供。
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
分析師對Fulcrum Treeutics(FULC)的評級正確嗎？
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a initiated with a price target of $0.00 to $5.00. The current price Fulcrum Therapeutics (FULC) is trading at is $4.17, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的支點治療公司(FULC)評級是以0.00美元至5.00美元的目標價啟動的。支點治療公司(FULC)目前的交易價格為4.17美元，在分析師的預測範圍內。